China Human Vaccine Industry Report, 2019-2025
  • Aug.2019
  • Hard Copy
  • USD $3,200
  • Pages:150
  • Single User License
    (PDF Unprintable)       
  • USD $3,000
  • Code: ZLC088
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $4,500
  • Hard Copy + Single User License
  • USD $3,400

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseases to the lowest level.

Following the vaccine scandal of Changsheng Bio-technology Co., Ltd. in 2018, the Vaccine Administration Law of the People’s Republic of China was enacted at the Eleventh Meeting of the Standing Committee of the 13th National People’s Congress on June 29th, 2019. The Law which is due to take effect on December 1, 2019, will be a boon for better regulation on the whole vaccine market and sound development of the vaccine industry.

The National Institutes for Food and Drug Control approved supply of 276.6 million doses (37 kinds of vaccines) to the market from January to July 2019. Thereof, China National Biotech Group (including Chengdu Institute of Biological Products Co., Ltd., Shanghai Institute of Biological Products Co., Ltd., Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd. and Changchun Keygen Biological Products Co., Ltd.) boasted the largest lot release volume, or 43.4% of the total, staying far ahead of others as the bellwether in the Chinese vaccine industry.


In China, homemade vaccines lead the market, and the imported take a small share (lower than 5%), especially in the EPI vaccines market which is in the monopoly of local big-name brands. That it takes one year to five years for imported vaccines to acquire the Imported Drug License helps explain why there are just several imported vaccines such as pentavalent vaccine, 13/23-valent pneumococcal vaccine and HPV vaccine available on the Chinese vaccine market.

Chinese vaccine companies have broken the monopoly of their foreign peers on new vaccines like 13-valent pneumococcal vaccine and HPV vaccine, in their race to spend more on research and development. In current stage, Walvax Biotechnology’s 13-valent pneumococcal vaccine has been applied for GMP certificate and is expected to be the first approved homemade vaccine of such kind in China in 2019; Beijing Wantai Biological Pharmacy Enterprise’s 2-valent HPV vaccine which was applied for launch in November 2017, undergoes the quick review by National Medical Products Administration, and is expected to be the first approved homemade vaccine of such sort in China in 2019.

China’s vaccine market will have a rosy prospect. The growing demand for vaccines comes with a large population base, the aging of population, more than 15 million newborns each year and the two-child policy. As people live a better life, they also demand more extra EPI vaccines.

China Human Vaccine Industry Report, 2019-2025 highlights the following:
20120114.gifChina’s human vaccine industry (environment, status quo, demand, market size, import and export, and competitive pattern);
20120114.gifChinese human vaccine market segments (demand, lot release volume and competitive pattern);
20120114.gif22 human vaccine companies (operation, vaccine business);
20120114.gifSummary and forecast.

1. Overview of Vaccine Industry
1.1 Definition & Classification
1.2 Industry Chain

2. China Human Vaccine Industry
2.1 Operating Environment
2.1.1 International Market
2.1.2 Policy Environment
2.1.3 Biopharmaceutical Market
2.2 Status Quo
2.3 Market Demand
2.4 Circulation Channels
2.5 Market Size
2.6 Import & Export
2.6.1 Import
2.6.2 Export
2.6.3 Average Price
2.7 Competition Pattern

3. Human Vaccine Market Segments in China
3.1 Hepatitis B Vaccine
3.1.1 Demand
3.1.2 Lot Release Volume
3.1.3 Competition Pattern
3.2 Meningococcal Vaccine
3.2.1 Demand
3.2.2 Lot Release Volume
3.2.3 Competition Pattern
3.2.4 Development Prospects
3.3 Hepatitis A Vaccine
3.3.1 Demand
3.3.2 Lot Release Volume
3.3.3 Competition Pattern
3.4 Influenza Vaccine
3.4.1 Demand
3.4.2 Lot Release Volume
3.4.3 Competition Pattern
3.4.4 Development Trend
3.5 Hib Vaccine
3.5.1 Demand
3.5.2 Lot Release Volume
3.5.3 Competition Pattern
3.5.4 Development Trend
3.6 Human Rabies Vaccine
3.6.1 Demand
3.6.2 Lot Release Volume
3.6.3 Competition Pattern
3.6.4 Development Trend
3.7 Varicella Vaccine
3.7.1 Demand
3.7.2 Lot Release Volume
3.7.3 Competition Pattern
3.7.4 Development Trend
3.8 Pneumococcal Vaccines
3.8.1 Demand
3.8.2 Lot Release Volume
3.8.3 Competition Pattern
3.8.4 Development Trend
3.9 DTP Vaccine
3.9.1 Demand
3.9.2 Lot Release Volume
3.9.3 Competition Pattern
3.9.4 Development Trend
3.10 Poliomyelitis Vaccine
3.10.1 Demand
3.10.2 Lot Release Volume
3.10.3 Competition Pattern
3.10.4 Development Trend
3.11 Hepatitis E Vaccine
3.11.1 Demand
3.11.2 Lot Release Volume
3.11.3 Competition Pattern

4. Major Human Vaccine Manufacturers in China
4.1 China National Biotech Group
4.1.1 Profile
4.1.2 National Vaccine & Serum Institute
4.1.3 Chengdu Institute of Biological Products Co., Ltd.
4.1.4 Shanghai Institute of Biological Products Co., Ltd.
4.1.5 Wuhan Institute of Biological Products Co., Ltd.
4.1.6 Lanzhou Institute of Biological Products Co., Ltd.
4.1.7 Changchun Institute of Biological Products Co., Ltd.
4.1.8 Changchun Keygen Biological Products Co., Ltd.
4.2 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 R&D and Investment
4.2.5 Production and Sales
4.2.6 Vaccine Business
4.2.7 Development Strategy
4.3 Hualan Biological Engineering Inc.
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 R&D
4.3.5 Vaccine Business
4.3.6 Development Strategy
4.4 Chongqing Zhifei Biological Products Co., Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 R&D
4.4.6 Development Dynamics
4.4.7 Development Strategy
4.5 Walvax Biotechnology Co, Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Revenue Structure
4.5.4 Gross Margin
4.5.5 R&D
4.5.6 Vaccine Business
4.5.7 Development Trend
4.6 Liaoning Cheng Da Co., Ltd.
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Gross Margin
4.6.5 Major Customers
4.6.6 R&D
4.6.7 Development Strategy
4.7 Shenzhen Kangtai Biological Products Co., Ltd.
4.7.1 Profile
4.7.2 Operation
4.7.3 Revenue Structure
4.7.4 Gross Margin
4.7.5 R&D
4.7.6 Development Strategy
4.8 Changsheng Bio-Technology Co., Ltd.
4.8.1 Profile
4.8.2 Operation
4.8.3 Revenue Structure
4.8.4 R&D
4.8.5 Development Dynamics
4.9 Olymvax Biopharmaceuticals Inc.
4.9.1 Profile
4.9.2 Operation
4.9.3 R&D
4.10 Sinovac Biotech Ltd.
4.10.1 Profile
4.10.2 Operation
4.10.3 Revenue Structure
4.10.4 Sinovac Biotech (Beijing)
4.11 Changchun BCHT Biotechnology Co. Ltd.
4.11.1 Profile
4.11.2 Operation
4.11.3 Development Dynamics
4.12 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
4.12.1 Profile
4.12.2 Operation
4.13 Tibet Amy Biotech & Vaccine Group Co., Ltd.
4.13.1 Profile
4.13.2 Vaccine Business
4.14 NCPC GeneTech Biotechnology Development Co., Ltd.
4.14.1 Profile
4.14.2 Operation
4.15 Dalian Aleph Biomedical Co., Ltd.
4.15.1 Profile
4.15.2 Vaccine Business
4.16 Beijing Minhai Biotechnology Co., Ltd.
4.16.1 Profile
4.16.2 Operation
4.17 CanSino Biologics Inc.
4.17.1 Profile
4.17.2 Operation
4.17.3 R&D and Investment
4.17.4 Development Strategy
4.18 Other Enterprises
4.18.1 Shenzhen Sanofi Pasteur Biological Products Co., Ltd.
4.18.2 Convac Biotechnology Co., Ltd.
4.18.3 Chengdu Kanghua Biological Products Co., Ltd.
4.18.4 Guangzhou Nuocheng Biological Products
4.18.5 CanSino Biologics Inc.

5. Summary and Forecast
5.1 Summary
5.2 Development Trends
5.2.1 Human Vaccine Industry is Increasingly Concentrated
5.2.2 Two-child Policy is in Favor of Human Vaccine Industry Growth
5.2.3 Faster Aging of Population Boosts Human Vaccine Industry
5.2.4 HPV Vaccine Has a Rosy Prospect and Is Expected to Be Localized
5.2.5 Homemade 13-valent Pneumococcal Conjugate Vaccine is Likely to be Launched
5.2.6 Local Companies Invest More Heavily in Research and Development of Vaccine Products Which are Becoming More Various
5.2.7 Demand for Extra EPI Vaccines Is Growing
Vaccine Industry Chain
Global Human Vaccine Market Size, 2010-2019
Global Human Vaccine Market Size, 2017-2025E
Revenue of Major Global Vaccine Companies, 2011-2019
Vaccine Sales Growth Rate of Major Global Vaccine Companies, 2012-2019
Global Top 5 Vaccines by Sales
R&D Pipelines of Global Top 4 Vaccine Giants 
Gross Industrial Output Value of China Biopharmaceutical Industry, 2008-2019
Gross Industrial Output Value of China Biopharmaceutical Industry, 2016-2025E
Lot Release Volume of Human Vaccine in China, 2013-2019
R&D of Homemade Vaccines of Large Varieties in China
China Human Vaccine Market Size, 2010-2019
Import Volume and Value of Human Vaccine in China, 2010-2019
Export Volume and Value of Human Vaccine in China, 2010-2019
Average Unit Export/Import Price of Human Vaccine in China, 2010-2019
Stratified Comparison between Local Vaccine Companies in China
Comparison of Products and R&D Pipelines between Leading Chinese Vaccine Companies, 2018
Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, 2018
Lot Release Volume Breakdown of Human Vaccines in China by Nature of Enterprise, Jan.-Jul.2019
Lot Release Volume of Human Vaccines in China by Enterprise, 2018
Lot Release Volume of Human Vaccines in China by Enterprise, Jan.-Jul.2019
Hepatitis B Morbidity and Mortality in China, 2013-2019
Lot Release Volume of Hepatitis B Vaccine in China, 2013-2019
Lot Release Volume of Hepatitis B Vaccine in China by Dosage Form, 2013-2019
Meningitis Morbidity and Mortality in China, 2013-2019
Meningococcal Vaccines Lot Release Volume in China, 2013-2019
Meningococcal Vaccines Lot Release Volume in China by Type, 2013-2019
Sanofi’s Menactra Sales and YoY Growth, 2015-2019
GSK’s Menveo Sales and YoY Growth, 2015-2019
R&D of Epidemic Cerebrospinal Meningitis Conjugate Vaccine in China
Hepatitis A Morbidity and Mortality in China, 2013-2019
Lot Release Volume of Hepatitis A Vaccine in China, 2013-2019
Influenza Morbidity and Mortality in China, 2013-2019
H7N9 Influenza Morbidity and Mortality in China, 2013-2019
Lot Release Volume of Influenza Vaccine in China, 2013-2019
Sanofi’s Influenza Vaccine Series Products Sales and YoY Growth, 2012-2019
GSK’s Influenza Vaccine Series Products Sales and YoY Growth, 2012-2019
Free Influenza Vaccination for Targeted Groups in Some Places of China
R&D of Quadrivalent Influenza Vaccine in China 
Lot Release Volume of Hib Vaccine in China, 2013-2019
Rabies Morbidity and Mortality in China, 2013-2019
Lot Release Volume of Human Rabies Vaccine in China, 2013-2019
R&D of Human Rabies Vaccine in China 
Lot Release Volume of Varicella Vaccine in China, 2013-2019
R&D of Varicella Vaccine in China 
Lot Release Volume of Pneumococcal Vaccines in China, 2013-2019
Comparison between Pneumococcal Vaccines Launched on Global Market
Global 7/13-valent Pneumococcal Vaccines Sales and YoY Change, 2006-2019
Global 23-valent Pneumococcal Vaccine Sales and YoY Change, 2009-2019
Key Chinese Companies’ Progress in R&D of 13-valent Pneumococcal Vaccine
Key Chinese Companies’ Progress in R&D of 23-valent Pneumococcal Vaccine
Pertussis Morbidity and Mortality in China, 2012-2019
Neonatal Tetanus Morbidity and Mortality in China, 2012-2019
Lot Release Volume of DTP Vaccine in China, 2013-2019
DTcP Vaccines Launched or Being Developed in China
Poliomyelitis Morbidity and Mortality in China, 2013-2019
R&D of Poliomyelitis Vaccine in China
Hepatitis E Morbidity and Mortality in China, 2012-2019
Lot Release Volume of Hepatitis E Vaccine in China, 2013-2019
Vaccine Varieties of Chengdu Institute of Biological Products
Revenue and Net Income of Beijing Wantai Biological Pharmacy Enterprise, 2016-2018
Revenue of Beijing Wantai Biological Pharmacy Enterprise by Product, 2016-2018
Revenue of Beijing Wantai Biological Pharmacy Enterprise by Region, 2016-2018
Beijing Wantai Biological Pharmacy Enterprise’s R&D Costs and % of Total Revenue, 2016-2018
Beijing Wantai Biological Pharmacy Enterprise’s Projects with Funds Raised by IPO
Output and Sales of Beijing Wantai Biological Pharmacy Enterprise by Product, 2016-2018
Hepatitis E Vaccine Capacity, Output and Capacity Utilization of Beijing Wantai Biological Pharmacy Enterprise, 2016-2018 
Revenue and Net Income of Hualan Biological Engineering, 2013-2019
Revenue Breakdown of Hualan Biological Engineering by Sector, 2013-2018
Revenue Structure of Hualan Biological Engineering by Sector, 2013-2018
R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2013-2018
Output & Sales Volume, Inventory of Hualan Biological Engineering, 2013-2018
Vaccine Revenue and Percentage of Hualan Biological Engineering, 2013-2018
Gross Margin of Hualan Biological Engineering, 2013-2018
Revenue and Net Income of Chongqing Zhifei Biological Products, 2012-2019
Gross Margin of Chongqing Zhifei Biological Products by Product, 2013-2018
R&D Costs and % of Total Revenue of Chongqing Zhifei Biological Products, 2011-2018
Revenue and Net Income of Walvax Biotechnology, 2013-2019
Gross Margin of Own Vaccine of Walvax Biotechnology, 2013-2018
R&D Costs and % of Total Revenue of Walvax Biotechnology, 2013-2018
Progress of Products under Registration Declaration of Walvax Biotechnology, as of 2018
Walvax Biotechnology’s Timeline of R&D and GMP Application of 13-valent Pneumococcal Vaccine
Revenue and Net Income of Liaoning Chengda, 2013-2019
Revenue Breakdown of Liaoning Chengda by Product, 2013-2018
Revenue Structure of Liaoning Chengda by Product, 2013-2018
Gross Margin of Liaoning Chengda, 2013-2018
R&D Costs and % of Total Revenue of Liaoning Chengda, 2014-2018
Revenue and Net Income of Shenzhen Kangtai Biological Products, 2013-2019
Gross Margin of Shenzhen Kangtai Biological Products, 2013-2018
R&D Costs and % of Total Revenue of Shenzhen Kangtai Biological Products, 2013-2018
Revenue and Net Income of Changsheng Bio-technology, 2014-2018
Revenue Breakdown of Changsheng Bio-technology by Product, 2014-2018
Revenue Structure of Changsheng Bio-technology by Product, 2014-2018
R&D Costs and % of Total Revenue of Changsheng Bio-technology, 2014-2018
Revenue and Net Income of Olymvax Biopharmaceuticals, 2014-2019
Main Products of Sinovac Biotech
Revenue and Net Income of Sinovac Biotech, 2013-2019
Financial Indices of Sinovac Biotech, 2015-2018
Financial Indices of Changchun BCHT Biotechnology, 2014-2019
Equity Structure of Zhejiang Tianyuan Bio-Pharmaceutical
Revenue and Net Income of Zhejiang Tianyuan Bio-Pharmaceutical, 2013-2016
Financial Indices of NCPC GeneTech Biotechnology Development, 2014-2018
Development History of CanSino Biologics
Consolidated Income of CanSino Biologics, 2016-2018
R&D Expenditure of CanSino Biologics, 2016-2018
R&D Pipelines of CanSino Biologics
Main Ebola Vaccines Being Developed Worldwide
Main Partners of CanSino Biologics
Products Being Researched by CanSino Biologics
China’s Vaccine Market Size, 2017-2025E
Number of Newborns in China, 2015-2025E
China’s Population Aged over 60 and % of Total Population, 2009-2018
Global Incidence of Cervical Cancer
Global 4/9-valent HPV Vaccines Sales and YoY Change (Merck Sharp & Dohme), 2009-2019
Global 2-valent HPV Vaccine Sales and YoY Change (GSK), 2008-2019
List of Countries Bringing HPV Vaccine into Vaccination Program (Those in Green Having Done This)
R&D Investment of Major Vaccine Companies in China, 2013-2018
Comparison between EPI Vaccine and Extra EPI Vaccine in China
Prices of Extra EPI Vaccines in China
Extra EPI Vaccines Paid by Medical Insurance and Financial Subsidy Policies in China by Region 
Classification of Vaccines
Main Mergers & Acquisitions in the Vaccine Industry Worldwide, 2005-2019
Related Policies in China Human Vaccine Industry, 2006-2019
EPI Human Vaccine Varieties in China
Top10 Human Vaccines by Lot Release Volume in China, 2018-2019
Main Human Vaccine Varieties and Producers Granted Permit for Lot Release in China, Jan.-Jul. 2019
China’s Human Vaccine Import Volume and Value by Country, 2018
Top 10 Countries/Regions of China Human Vaccine Export, 2018
Human Vaccine Lot Release Volume of Major Vaccine Enterprises in China, 2014-2019
Vaccine Revenue of Major Human Vaccine Enterprises in China, 2013-2019
Hepatitis B Morbidity and Mortality in China, Jan-Jun 2019
Lot Release Volume of Major Hepatitis B Vaccine Companies in China, 2013-2019
Share of Major Hepatitis B Vaccine Companies by Lot Release Volume in China, 2013-2019
Meningitis Morbidity and Mortality in China, Jan.-Jun. 2019
Lot Release Volume of Major Meningococcal Vaccines Companies in China, 2013-2019
Share of Major Meningococcal Vaccines Companies by Lot Release Volume in China, 2013-2019
Hepatitis A Morbidity and Mortality in China, Jan.-Jun. 2019
Lot Release Volume of Major Hepatitis A Vaccine Companies in China, 2013-2019
Share of Major Hepatitis A Vaccine Companies by Lot Release Volume in China, 2013-2019
Influenza Morbidity and Mortality in China, Jan.-Jun. 2019
H7N9 Influenza Morbidity and Mortality in China, Jan.-Jun. 2019
Lot Release Volume of Major Influenza Vaccine Companies in China, 2013-2019
Share of Major Influenza Vaccine Companies by Lot Release Volume in China, 2013-2019
Lot Release Volume of Major Hib Vaccine Companies in China, 2013-2019
Share of Major Hib Vaccine Companies by Lot Release Volume in China, 2013-2019
Rabies Morbidity and Mortality in China, Jan.-Jun. 2019
Lot Release Volume of Major Human Rabies Vaccine Companies in China, 2013-2019
Share of Major Human Rabies Vaccine Companies by Lot Release Volume in China, 2013-2019
Lot Release Volume of Major Varicella Vaccine Companies in China, 2013-2019
Share of Major Varicella Vaccine Companies by Lot Release Volume in China, 2013-2019
Lot Release Volume of Major Pneumococcal Vaccines Companies in China, 2013-2019
Share of Major Pneumococcal Vaccine Companies by Lot Release Volume in China, 2013-2019
Pertussis Morbidity and Mortality in China, Jan.-Jun. 2019
Neonatal Tetanus Morbidity and Mortality in China, Jan.-Jun. 2019
Lot Release Volume of Major DTP Vaccine Companies in China, 2013-2019
Share of Major DTP Vaccine Companies by Lot Release Volume in China, 2013-2019
Lot Release Volume of Poliomyelitis Vaccine Companies in China, 2013-2019
Share of Major Poliomyelitis Vaccine Companies by Lot Release Volume in China, 2013-2019
Hepatitis E Morbidity and Mortality in China, Jan.-Jun. 2019
Lot Release Volume of Major Hepatitis E Vaccine Companies in China, 2013-2019
Specifications and Place of Origin of China National Biotech Group’s Main Vaccine Products
Vaccine Varieties of Shanghai Institute of Biological Products
Operation of Shanghai Institute of Biological Products, 2013-2016
Main Products Chongqing Zhifei Biological Products is Selling or Promoting according to Agreements, and Their Purposes
Revenue Breakdown of Chongqing Zhifei Biological Products by Product, 2014-2018
Lot Release Volume Breakdown of Chongqing Zhifei Biological Products by Product, 2014-2018
Revenue Breakdown of Chongqing Zhifei Biological Products by Region, 2014-2018
Projects under Registration Process of Chongqing Zhifei Biological Products, as of 2018
Progress of Preclinical Projects of Chongqing Zhifei Biological Products by 2018
Revenue Breakdown of Walvax Biotechnology by Product, 2014-2018
Revenue Breakdown of Walvax Biotechnology by Region, 2014-2018
Progress of Walvax Biotechnology’s Projects with Raised Fund, as of 2018
Output & Sales Volume, Inventory of Walvax Biotechnology, 2014-2018
Lot Release Volume of Walvax Biotechnology, 2014-2019
Liaoning Chengda’s Revenue from Top5 Customers and % of Total Revenue, 2015-2018
Main Products and Their Purposes of Shenzhen Kangtai Biological Products
Capacity, Output & Sales Volume of Shenzhen Kangtai Biological Products, 2013-2018
Revenue Breakdown of Shenzhen Kangtai Biological Products by Product, 2015-2018
Lot Release Volume and Percentage of Shenzhen Kangtai Biological Products, 2015-2018
Revenue Breakdown of Shenzhen Kangtai Biological Products by Region, 2015-2018
Progress of Research Projects of Shenzhen Kangtai Biological Products, as of 2018
Major Non-equity Investments by Shenzhen Kangtai Biological Products, as of 2018
Output & Sales Volume, Inventory of Changsheng Bio-technology, 2014-2018
Progress of Ongoing Projects of Changsheng Bio-technology as of the end of 2018
Development Course of Olymvax Biopharmaceuticals
Research Progress of Products Developed by Olymvax Biopharmaceuticals
Revenue Breakdown of Sinovac Biotech by Product, 2013-2018
Equity Structure of Sinovac Biotech
Vaccine Products of Zhejiang Tianyuan Bio-Pharmaceutical
Equity Structure of Dalian Aleph Biomedical
Development Goals of Dalian Aleph Biomedical
Financial Indices of Beijing Minhai Biotechnology, 2015-2018
Total Assets and Revenue of Shenzhen Sanofi Pasteur Biological Products, 2016
HPV Vaccine Products Worldwide
Lot Release Volume of HPV Vaccine in China by Enterprise, Jan-Jul 2019
Major HPV Vaccine Developers in China and Their Progress
Major 13-valent Pneumococcal Conjugate Vaccine Developers in China and Their R&D Progress
Main Vaccine Products Being Researched by Companies in China and Their Progress

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号